GIP Receptor Research: The Incretin Receptor the Field Cannot Agree On

The GIP receptor is the only major metabolic target where agonism and antagonism are both being pursued clinically. What the published literature reports.

By Published Updated

There are two incretin hormones. One of them, glucagon-like peptide-1, has a receptor whose pharmacology is settled to the point of being routine. The other, glucose-dependent insulinotropic polypeptide, has a receptor at which the field is actively pursuing two opposite strategies at once — agonism and antagonism — and cannot yet say which is right.

That disagreement is the most interesting thing about this receptor, and it is what this article is organised around. It describes research. It contains no guidance of any kind on handling any material, and it favours neither side of the argument it reports.

What the receptor is

The glucose-dependent insulinotropic polypeptide receptor, GIPR, is a class B1 — secretin-like — G protein-coupled receptor. It was cloned in 1993 and characterised as a member of the secretin–vasoactive intestinal peptide receptor family, distributed widely across peripheral organs and the brain [2]. Like the other members of its family relevant here, it couples through Gs to adenylate cyclase, raising intracellular cyclic AMP.

Its ligand, GIP, is released from enteroendocrine K cells of the proximal small intestine in response to nutrient intake — the other half of the incretin effect, alongside GLP-1 from L cells further down the gut. The two hormones together account for the observation that oral glucose produces a larger insulin response than intravenous glucose at matched blood concentrations, and their joint biology was reviewed together in 2007 in what remains a standard account [3].

The breadth of its distribution is worth pausing on, because it is not what the name suggests. "Gastric inhibitory polypeptide receptor" names a gut hormone, but the 1993 characterisation found the receptor in peripheral organs and the brain generally, not in a small number of tissues [2]. That breadth is part of why its pharmacology has been harder to settle than GLP-1's.

The disagreement, stated plainly

The GIP receptor is the only major target in this part of the library where two opposite pharmacological strategies are both supported by published rationale and both in clinical development.

The case for agonism. GIP is an incretin, so agonism at its receptor contributes glucose-dependent insulin secretion in the same way GLP-1 receptor agonism does. Beyond that, the argument runs through tolerability and through effects at receptors outside the pancreas. A contemporary statement of this case, setting out the mechanistic and clinical rationale for GIP receptor agonism, was published in 2025 [15].

The case for antagonism. The opposing argument draws on human genetics — loss-of-function variation at the receptor and its associations — and on physiological reasoning about what GIP does in the context of nutrient excess rather than in the context of a single meal. The case for antagonism was set out in a companion review published alongside the agonism case, in the same journal and year [14].

The fact that both are being pursued. Investigational and emerging GIP receptor-based therapies have been reviewed as a class, and the review covers programmes on both sides of the question [11]. A 2026 review addresses the situation directly in its title: one receptor, two opposite approaches, compared on efficacy and tolerability [18].

An observation about what that means for reading the literature. When a field pursues opposite strategies at one target, it is usually because the target's contribution depends on context — on which tissue, on what else is happening, on chronic versus acute engagement. Statements that begin "GIP receptor activation does X" should be read with that in mind, and this article avoids making them.

Where GIPR sits in multi-agonist design

In vitro research

The GIP receptor is the arm that distinguishes the dual and triple agonists from the single-receptor GLP-1 analogues, and the in vitro characterisations are where each molecule's relationship to it is defined.

Tirzepatide is built on a GIP backbone engineered to acquire GLP-1 receptor activity, rather than the other way round. It is characterised as an imbalanced dual agonist: activity at the GIP receptor comparable to native GIP, with weaker relative activity at the GLP-1 receptor than native GLP-1 [4]. That imbalance is deliberate and is the compound's defining in vitro property.

Retatrutide engages three receptors and is characterised as balanced between the glucagon and GLP-1 receptors with relatively greater activity at the GIP receptor [8]. So both of the most-studied multi-agonists in this family are weighted toward GIPR.

Two cautions. These characterisations come from different papers using different assay formats and reference standards, so the GIPR potencies reported for two compounds are not interchangeable. And potency at a cloned receptor in a transfected cell line is not a proportional predictor of effect in tissue — particularly for a receptor distributed as widely as this one, where which tissue is engaged may matter more than how strongly.

What the human research at this receptor reports

Human clinical research

Results from pharmaceutical clinical trials describe the investigational material and populations used in those studies and should not be interpreted as establishing the effects of research-grade materials offered for laboratory use.

There is an important structural point about this evidence base that has to come before any of the numbers: no published trial isolates the GIP receptor arm. Every clinical result attributed to GIP receptor agonism comes from a molecule that also engages the GLP-1 receptor. No compound in clinical development engages GIPR alone, and no trial has subtracted one arm from the other in humans.

So what follows is the clinical record of GIPR-containing molecules, not the clinical record of GIPR.

Type 2 diabetes. SURPASS-1 randomised 478 adults with type 2 diabetes inadequately controlled by diet and exercise alone. Mean glycated haemoglobin fell by 1.87% to 2.07% across the three groups against +0.04% for placebo at 40 weeks, with 87% to 92% of participants reaching a value below 7.0% against 20% on placebo [5].

Obesity. SURMOUNT-1 randomised 2,539 adults without diabetes. Mean percentage change in body mass at week 72 was −15.0%, −19.5% and −20.9% across groups against −3.1% for placebo [7].

Against a single-receptor comparator. SURPASS-2 randomised 1,879 participants with type 2 diabetes on metformin against semaglutide 1 mg, open-label, over 40 weeks. Estimated mean glycated haemoglobin change was −2.01, −2.24 and −2.30 percentage points against −1.86 with the comparator, with differences of −0.15 (P = 0.02), −0.39 and −0.45 percentage points (P < 0.001 for both) [6]. SURMOUNT-5 repeated the comparison in 751 adults with obesity and without type 2 diabetes over 72 weeks, reporting least-squares mean percentage change in body mass of −20.2% against −13.7%, P < 0.001 [13].

Those two trials are the closest the literature comes to an experiment about adding a GIP arm — and they are not that experiment. The two compounds differ in backbone, in GLP-1 receptor potency and in albumin chemistry as well as in GIPR engagement, so the difference between them cannot be attributed to the GIP arm alone. Published systematic analyses of approved incretin mimetics note the general form of this problem for indirect and cross-compound comparison [12].

Cardiovascular outcomes. SURPASS-CVOT randomised 13,299 participants with type 2 diabetes and atherosclerotic cardiovascular disease against dulaglutide 1.5 mg — an active comparator, not placebo. The primary composite occurred in 12.2% against 13.1%, hazard ratio 0.92, 95.3% CI 0.83 to 1.01: noninferiority met, superiority not demonstrated [16].

Triple agonism. The clinical record for molecules engaging GIPR alongside both GLP-1R and GCGR is younger. Phase 2 trials reported in obesity and in type 2 diabetes [9, 10], and the first phase 3 result, TRANSCEND-T2D-1, reported mean glycated haemoglobin change of −1.69% to −1.94% against −0.81% for placebo at 40 weeks [17].

Tolerability. Gastrointestinal events dominate the adverse-event tables of every trial of every GIPR-containing molecule, as they do for single-receptor GLP-1 agonists. Whether the GIP arm modifies that pattern is one of the specific questions the agonism case rests on [15], and no trial isolating the arm has tested it.

What the animal and genetic evidence contributes

Animal research

The preclinical literature is where the case for each strategy is principally argued, and the two reviews cited above summarise very different bodies of it.

On the agonism side, the rodent characterisations that accompanied the discovery of the dual and triple agonists report the metabolic profile of GIPR-containing molecules in diet-induced obesity models [4, 8]. In the tri-agonist case the rodent work separated the contributions of the three arms, attributing reduced calorie intake to the GIP and GLP-1 receptor arms jointly and an increase in whole-body metabolic rate to the glucagon arm [8] — note that even there, the two incretin arms are treated together rather than separated from one another.

On the antagonism side, the published rationale draws on loss-of-function models and on human genetic association, set out in the antagonism review [14]. The comparison of the two approaches on efficacy and tolerability grounds is the subject of a dedicated 2026 review [18].

Findings described in this section were observed in animals or derive from genetic association rather than from intervention in humans. Nothing in them establishes anything about humans directly, and the existence of well-argued reviews on both sides is itself the clearest evidence that the preclinical record does not settle the question.

What would settle it, and why it has not been run

The experiment the field lacks is straightforward to describe and difficult to run: a trial that engages the GIP receptor alone, or that compares two otherwise-identical molecules differing only in their GIPR activity.

Neither exists. No compound in clinical development engages GIPR alone. And the pair of molecules that would make a clean comparison — identical backbone, identical albumin chemistry, identical GLP-1 receptor potency, differing only at GIPR — has not gone into a trial.

Until one of those is done, three things follow for reading this literature. Clinical results attributed to GIP receptor agonism are results for molecules that also do something else. The comparison between a GIPR-containing dual agonist and a single-receptor agonist is a comparison of two whole molecules, not of one arm. And the disagreement between the agonism and antagonism cases is not going to be resolved by more trials of multi-agonists, because those trials cannot address it.

All the clinical research described in this article studied pharmaceutical material, manufactured to a regulatory standard, administered under registered protocols in defined populations under clinical supervision. None of it is research into, or evidence about, research-grade material supplied for laboratory use.

Frequently Asked Questions

What is the GIP receptor?
A class B1, secretin-like G protein-coupled receptor, cloned in 1993 and shown to be distributed widely across peripheral organs and the brain [2]. It couples through Gs to raise intracellular cyclic AMP. Its ligand, glucose-dependent insulinotropic polypeptide, is released from enteroendocrine K cells of the proximal small intestine and is one of the two incretin hormones [3].
Why are both agonists and antagonists at this receptor in development?
Because both have published mechanistic rationales and neither has been ruled out. The case for agonism and the case for antagonism were set out in companion reviews in the same journal and year [15, 14], and a 2026 review addresses the two approaches side by side [18]. Programmes on both sides have been reviewed as a class [11].
Which compounds engage the GIP receptor?
Tirzepatide, a dual agonist at GIPR and GLP-1R built on a GIP backbone [4], and retatrutide, a triple agonist that adds the glucagon receptor [8]. Both are characterised in vitro as weighted toward GIPR relative to their GLP-1 receptor activity.
Has any trial tested GIP receptor agonism on its own?
No. No compound in clinical development engages GIPR alone, and no published trial isolates the GIP arm from the GLP-1 arm in humans. Every clinical result attributed to GIP receptor agonism comes from a molecule that also engages the GLP-1 receptor.
Do the head-to-head trials show what the GIP arm adds?
Not on their own. SURPASS-2 and SURMOUNT-5 compared a GIPR-containing dual agonist with a single-receptor GLP-1 agonist and reported differences on their primary endpoints [6, 13]. But the two compounds differ in backbone, GLP-1 receptor potency and albumin chemistry as well as in GIPR engagement, so the difference between them cannot be attributed to the GIP arm alone.
What cardiovascular evidence exists for a GIPR-containing compound?
SURPASS-CVOT randomised 13,299 participants with type 2 diabetes and atherosclerotic cardiovascular disease against dulaglutide 1.5 mg, an active comparator. The primary composite occurred in 12.2% against 13.1%, hazard ratio 0.92 — noninferiority met, superiority not demonstrated [16]. It is an active-comparator result and is not readable against placebo-controlled outcome trials of other compounds.
Is the GIP receptor the same as the GLP-1 receptor?
No. They are separate gene products, though both are class B1 receptors that couple through Gs, and their ligands belong to the same peptide superfamily with substantial sequence homology [2, 1]. That homology is what makes a single molecule capable of engaging both, which is the structural basis of every dual and triple agonist in this family.

References

  1. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1 Proceedings of the National Academy of Sciences of the United States of America; 1992. PMID 1326760 doi:10.1073/pnas.89.18.8641
  2. Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain Endocrinology; 1993. PMID 8243312 doi:10.1210/endo.133.6.8243312
  3. Biology of incretins: GLP-1 and GIP Gastroenterology; 2007. PMID 17498508 doi:10.1053/j.gastro.2007.03.054
  4. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept Molecular Metabolism; 2018. PMID 30473097 doi:10.1016/j.molmet.2018.09.009
  5. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial The Lancet; 2021. PMID 34186022 doi:10.1016/S0140-6736(21)01324-6
  6. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes The New England Journal of Medicine; 2021. PMID 34170647 doi:10.1056/NEJMoa2107519
  7. Tirzepatide Once Weekly for the Treatment of Obesity The New England Journal of Medicine; 2022. PMID 35658024 doi:10.1056/NEJMoa2206038
  8. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept Cell Metabolism; 2022. PMID 35985340 doi:10.1016/j.cmet.2022.07.013
  9. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial The New England Journal of Medicine; 2023. PMID 37366315 doi:10.1056/NEJMoa2301972
  10. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA The Lancet; 2023. PMID 37385280 doi:10.1016/S0140-6736(23)01053-X
  11. Investigational and emerging gastric inhibitory polypeptide (GIP) receptor-based therapies for the treatment of obesity Expert Opinion on Investigational Drugs; 2024. PMID 38984950 doi:10.1080/13543784.2024.2377319
  12. Comparative efficacy and tolerability of currently approved incretin mimetics: A systematic analysis of placebo-controlled clinical trials Diabetes, Obesity and Metabolism; 2025. PMID 40212008 doi:10.1111/dom.16398
  13. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity The New England Journal of Medicine; 2025. PMID 40353578 doi:10.1056/NEJMoa2416394
  14. GIP Receptor Antagonists in the Pharmacotherapy of Obesity: Physiologic, Genetic, and Clinical Rationale Diabetes; 2025. PMID 40521869 doi:10.2337/dbi24-0027
  15. A Contemporary Rationale for Agonism of the GIP Receptor in the Treatment of Obesity Diabetes; 2025. PMID 40521890 doi:10.2337/dbi24-0026
  16. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes The New England Journal of Medicine; 2025. PMID 41406444 doi:10.1056/NEJMoa2505928
  17. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial The Lancet; 2026. PMID 42250575 doi:10.1016/S0140-6736(26)00967-0
  18. One receptor, two opposite approaches: efficacy and tolerability of GIPR agonism and antagonism in obesity pharmacotherapy Appetite; 2026. PMID 42492687 doi:10.1016/j.appet.2026.108723

Every identifier above is resolved against PubMed, Crossref or ClinicalTrials.gov at build time, and the title returned by the register is compared with the title stored here. A page does not publish if a reference fails to resolve.

Research-Use Information

For in vitro research use only. This material is a laboratory reagent. It is not a drug, food, dietary supplement, or cosmetic and is not for human or veterinary use, including ingestion, injection, or any other administration. No information on this page describes or implies any effect in humans or animals. Sold only to researchers under our Terms of Sale.